✦ LIBER ✦

A Critical Evaluation ofTm(FTIR)Measurements of High-Concentration IgG1Antibody Formulations as a Formulation Development Tool

✍ Scribed by Susanne Matheus; Hanns-Christian Mahler; Wolfgang Friess

Book ID: 106492807
Publisher: Springer US
Year: 2006
Tongue: English
Weight: 331 KB
Volume: 23
Category: Article
ISSN: 0724-8741
DOI: 10.1007/s11095-006-0283-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Characterization of the photodegradation

Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form

✍ Pei Qi; David B. Volkin; Hui Zhao; Michael L. Nedved; Robert Hughes; Ryan Bass; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 412 KB

Evaluation of the iCE280 Analyzer as a p

Evaluation of the iCE280 Analyzer as a potential high-throughput tool for formulation development

✍ Ning Li; Kendall Kessler; Laura Bass; David Zeng 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 535 KB

Development of a microflow digital imagi

Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation

✍ Klaus Wuchner; Jochen Büchler; Rene Spycher; Paul Dalmonte; David B. Volkin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 260 KB

The development of a Microflow digital imaging (MDI) method to detect and monitor protein particulates in a high concentration IgG1 monoclonal antibody formulation is presented. The MDI assay was optimized and qualified as a characterization assay in terms of accuracy and precision of particle size

Application of a high-throughput screeni

Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies

✍ Todd J. Gibson; Katie Mccarty; Iain J. Mcfadyen; Ethan Cash; Paul Dalmonte; Kenn 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 380 KB

Protein solubility is a critical attribute in monoclonal antibody (mAb) formulation development as insolubility issues can negatively impact drug stability, activity, bioavailability, and immunogenicity. A high-throughput adaptation of an experimental method previously established in the literature